CREATING A NEW CLASS OF RECEPTOR TARGETED GENETIC MEDICINES

Selective modulation of gene targets in the disease tissue to achieve superior efficacy and safety

Dark%20blue%20gradeint%20overlay_edited.

Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases.

ABOUT US

Aro is a product-focused platform company, developing a wholly owned proprietary pipeline and a partnered pipeline of Centyrin-RNA drug conjugates to address previously intractable diseases.

OUR SCIENCE

We discover and optimize receptor-specific Centyrins and conjugate them to oligonucleotides to precisely modulate gene targets in disease tissues.

JOIN US

If you are interested in working on the cutting edge of genetic medicine and making a meaningful difference in patients' lives, come join our team!

LATEST NEWS

February 6, 2024

Aro Biotherapeutics to Present Updates on ABX1100, a CD71 Centyrin – Gys1 siRNA Conjugate for the Treatment of Pompe Disease at the 20th Annual WORLD Symposium 2024 Meeting

November 28, 2023

Aro Biotherapeutics Secures $41.5M Series B Financing

October 25, 2023

Aro Biotherapeutics Announces Start of First in Human Study with ABX1100, a Novel First in Class Centyrin-siRNA Conjugate in Development for Pompe Disease